Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test

Primary human papillomavirus (HPV) testing (without concurrent Pap tests) every 3 years is under consideration in the United States as an alternative to the two recommended cervical cancer screening strategies: primary Pap testing every 3 years, or concurrent Pap and HPV testing (“cotesting”) every...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Gage, Julia C., Schiffman, Mark, Katki, Hormuzd A., Castle, Philip E., Fetterman, Barbara, Wentzensen, Nicolas, Poitras, Nancy E., Lorey, Thomas, Cheung, Li C., Kinney, Walter K.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2014
Sujets:
Brief Communication
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4111283/
https://ncbi.nlm.nih.gov/pubmed/25038467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju153
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires